Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

<jats:title>Abstract</jats:title><jats:p>Proteasomes catalyse the degradation of endogenous proteins into oligopeptides, but can concurrently create spliced oligopeptides through ligation of previously non-contiguous peptide fragments. Recent studies have uncovered a formerly unappreciated role for proteasome-catalysed peptide splicing (PCPS) in the generation of non-genomically templated human leukocyte antigen class I (HLA-I)-bound <jats:italic>cis-</jats:italic>spliced peptides that can be targeted by CD8<jats:sup>+</jats:sup> T cells in cancer and infection. However, the mechanisms defining PCPS reactions are poorly understood. Here, we experimentally define the biochemical constraints of proteasome-catalysed <jats:italic>cis</jats:italic>-splicing reactions by examination of <jats:italic>in vitro</jats:italic> proteasomal digests of a panel of viral- and self-derived polypeptide substrates using a tailored mass-spectrometry-based <jats:italic>de novo</jats:italic> sequencing workflow. We show that forward and reverse PCPS reactions display unique splicing signatures, defined by preferential fusion of distinct amino acid residues with stringent peptide length distributions, suggesting sequence- and size-dependent accessibility of splice reactants for proteasomal substrate binding pockets. Our data provide the basis for a more informed mechanistic understanding of PCPS that will facilitate future prediction of spliced peptides from protein sequences.</jats:p>

Original publication

DOI

10.1101/2020.04.05.025908

Type

Journal article

Publisher

Cold Spring Harbor Laboratory

Publication Date

06/04/2020